Thank you, Rich. Most importantly SUNS portfolio has remained 100% performing throughout the current economic slowdown in early stages of recovery. This performance is a tremendous complement to the financial sponsors and portfolio companies and management teams that we have invested in. In addition, SUNS defensive portfolio and performance supports our underwriting thesis of minimizing risk of loss by investing in first-lien loans at the top of the capital structure, in non-cyclical industries as well as allocating a significant portion of our exposure to collateralized loans to our specialty finance verticals. At quarter end, the weighted average investment risk rating of our portfolio improved to 1.9 based on our 1 to 4 risk rating scale with 1 representing the least amount of risk. SUNS comprehensive portfolio totaled $522 million at quarter end and was highly diversified encompassing over 200 borrowers across 120 industries. Roughly 50% of the portfolio was invested in first lien asset-based and life science loans with the remaining 50% in senior secured first lien cash flow loans. Our largest industry exposures were healthcare services, professional services, and insurance services. The average investment per issuer was $2.5 million or less than 0.5% of the total portfolio. At September 30, approximately 100% of our portfolio consisted in senior secured loans comprised of 98.4% in first lien and 1.5% in second lien secured loans. Approximately 87% of our portfolio has a LIBOR floor and at quarter end, all of our borrowers made their interest rate payments. We believe that our efforts to position this portfolio to first lien loans, which carry less risk than second lien and subordinated loans, will result in greater capital preservation during the ongoing economic recovery. At quarter end, our weighted average asset level yield was 9.4% at fair value. By focusing on our commercial finance verticals we’ve been able to maintain a portfolio yield approaching 10% despite the sharp drop in LIBOR. Including activity across our business lines originations for the third quarter totaled $40 million and repayments were approximately $55 million. Now let me provide an update on our investment verticals. Let’s start with cash flow. We believe that our cash flow portfolio is well-positioned to perform either during a continued economic recovery or mild downturn given our lack of direct exposure to cyclical industries. Substantially all of our cash flow companies are outperforming their COVID revised budgets for the year as a rebound in revenues, as well as cost cuts, have had a positive impact on their overall financial performance as well as liquidity position. We view the majority of our portfolio companies is providing essential services in non-cyclical sectors that will continue to be required during periods of regional stay in place mandates that may lie ahead. During the third quarter, none of our borrowers experience payment defaults. In particular, our healthcare cash flow loans have been performing extremely well. We attribute this both to the recession-resilient an essential service nature of the healthcare industry, as well as our underwriting edge. This stems not only from our experienced healthcare cash flow team but also the proprietary reimbursement and industry insights through both our Life Science and Gemino Healthcare asset-based lending team. At quarter end, our cash flow portfolio was just over $267 million or approximately 51% of the total portfolio. It encompassed 30 years – 30 issuers with an average investment of approximately $9 million. Over 97% of this portfolio is first lien assets with only one second lien in that portfolio. Post-quarter end, our one second lien investment was repaid at par, which now results in a 100% first lien portfolio. Our cash flow portfolio companies had a weighted average EBITDA of over $110 million. The weighted average yield on our cash flow portfolio was 6.6%. During the quarter we originated $7 million of first lien loans and experienced repayments of approximately $39 million. We are encouraged that sponsor activity has picked up with higher M&A volumes during the fourth quarter. We expect the sponsor led momentum to carry forward into the end of this year and the beginning of next year, which we believe will provide opportunities to invest in attractive upper mid-market companies. Now let me turn to our asset-based lending businesses. As a reminder, SUNS owns two commercial finance companies that specialize in making asset-based loans secured by accounts receivable. These companies led to – lend to small and mid-sized U.S. businesses that typically have limited access to more traditional bank financing. Gemino is focused on providing accounts receivable lines of credit to healthcare service providers, such as hospitals, skilled nursing, medical laboratories, and others. Collateral includes receivables from Medicare, Medicaid as well as private pay North Mill finances company is operating primarily in the distribution business services and manufacturing industries. North Mill is typically the sole lender to its borrowers and its financing structures predominantly include accounts receivable financing and factoring agreements. Both Gemino and North Mill are led by teams of seasoned professionals who have built careers in asset-based lending for anywhere from 25 to 40 years. The teams are therefore experienced, risk underwriters across multiple economic cycles. Their business models are highly resilient relationship-driven and serve as a lifeline of working capital to small businesses across the U.S. In prior economic downturns asset-based loans collateralized by accounts receivable have generally provided higher recovery rates than those supported only by cash flows. Let me now provide an update on both North Mill and Gemino. At quarter end, North Mill’s portfolio was approximately $155 million, representing just under 30% of SUNS’ total portfolio. The portfolio rebounded during the third quarter from the second quarter lows led by increased utilization of the facilities as well as new originations. The portfolio consists of over 130 borrowers with an average investment of $1.2 million. Over 99% of its borrowers are deemed essential businesses and the PPP has been highly beneficial to North Mill’s portfolio companies. North Mill has performed well and has not had a single payment default during the pandemic. We are very pleased with its credit quality. North Mill’s portfolio yield during the third quarter was approximately 13%. During the third quarter, North Mill funded $32 million of new investments and had repayments of $12 million. North Mill’s pipeline remains strong heading into the fourth quarter both from existing utilization of revolvers outstanding, as well as new transactions. For the third quarter, North Mill paid SUNS a cash dividend of $1.25 million consistent with the prior quarter. Now, let me turn to Gemino. At quarter end, Gemino’s portfolio was $70 million, representing just under 14% of the total SUNS portfolio. We believe that Gemino’s portfolio is now in a position to re-grow after experiencing significant repayment activity in the second quarter, which was resulting from the borrowers choosing to pay down their credit facilities with proceeds from government stimulus programs. The total number of Gemino’s clients has remained remarkably consistent and is comprised of loans to 34 issuers with an average loan of just over $2 million. The portfolio remains 100% performing. The impairment risk remains extremely low given Gemino’s disciplined underwriting and focused on financing healthcare service providers. We have high-quality accounts receivable supporting the working capital facilities. Cash collections typically go right into Gemino’s lockboxes, where they can deduct their fees and interest payments and amortization automatically. The weighted average asset level yield of Gemino’s portfolio was approximately 12.5% for the third quarter. During the quarter, Gemino had new fundings of less than $1 million. However, repayments were only $5 million. Pipeline activity is by given the government stimulus program, but it is starting to rebuild, as we head toward year-end. For the quarter Gemino paid SUNS a cash dividend of just under $1 million consistent with the prior quarter. As we look forward we are confident, not only in the portfolio quality of Gemino but believe that the company is well-positioned to capture additional growth as the market settles and funding under revolving credit facilities return to more normal levels. And finally, let me give an update on our life science business. Overall, our life science portfolio is largely insulated from short-term market and economic dislocations are given the long-dated equity investment periods, as well as product cycles. The impact of COVID-19 has been de minimis. 100% of our life science loans are performing and we continue to expect to incur no losses in this segment. As a reminder, we have never realized a loss in life science loans. Currently, 100% of our portfolio has more than 12 months of cash runway, so, substantial liquidity. At quarter end, the portfolio totaled $28 million across eight borrowers with an average investment of $3.5 million. There were negligible originations and no repayments. The weighted average yield on this portfolio was approximately 9.3% excluding any success fees or warrants. In summary, we believe SUNS portfolio is extremely well-positioned to weather and improving, but still challenging period given the uncertainties of the pandemic and the direction of the economy. We remain in close contact with our portfolio companies, their management teams and sponsors we support them as well as we work closely with our extensive network of relationships to support new investments. Solar Capital Partners’ commercial finance platform and significant dry powder enable us to provide structured solutions including cash flow and asset-based loans for capital-constrained companies. Solar Senior will be able to participate in these financings while maintaining significant diversification across our portfolio. Now let me turn the call back to Michael.